KFA Private Wealth Group LLC Grows Position in Johnson & Johnson $JNJ

KFA Private Wealth Group LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 4.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,072 shares of the company’s stock after purchasing an additional 239 shares during the quarter. KFA Private Wealth Group LLC’s holdings in Johnson & Johnson were worth $775,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of JNJ. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $35,000. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $48,000. Finally, von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the first quarter worth about $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE:JNJ opened at $190.66 on Monday. The firm’s 50 day moving average price is $178.48 and its 200 day moving average price is $163.78. The stock has a market cap of $459.16 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $24.02 billion for the quarter. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on JNJ shares. JPMorgan Chase & Co. increased their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Bank of America increased their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $192.94.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.